0001209191-20-029837.txt : 20200515
0001209191-20-029837.hdr.sgml : 20200515
20200515175943
ACCESSION NUMBER: 0001209191-20-029837
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200513
FILED AS OF DATE: 20200515
DATE AS OF CHANGE: 20200515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Foley Todd
CENTRAL INDEX KEY: 0001473930
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 20887160
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-13
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001473930
Foley Todd
C/O MPM ASSET MANAGEMENT
450 KENDALL STREET
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2020-05-13
4
S
0
1837
20.04
D
2231877
I
See Footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The shares were sold as follows: 1,768 by MPM BioVentures V, L.P. ("BV V") and 69 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.135. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,148,415 by BV V and 83,462 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
/s/ Todd Foley
2020-05-15